Skip to main content
News
Events
Contact us
Close Search
search
Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
search
News
Filter
All
All
Company interviews
Featured
Features
Interviews
Portfolio news
Team interviews
Uncategorized
Our partnership with CSL
We welcome VISCHER as our new domain partner
Podcast: How to build a compelling pitch deck for early stage ventures
KPMG renews partnership with BaseLaunch
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
Synendos Therapeutics granted EMA clinical trial authorisation
William Pao joins Alentis Therapeutics as independent board member
Novo Nordisk becomes a BaseLaunch partner
Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement
TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance
T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs
FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment
Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04
FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson
Onena Medicines secures 3.7 M Swiss francs investment
Johnson & Johnson Innovation renews its commitment
Cimeio collaborating with the University of Pennsylvania
Insights into Roche’s partnering and venture fund strategies
Salvina Therapeutics joins BaseLaunch portfolio
TOLREMO therapeutics secures USD 39 million
Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04
What you need to know about building your biotech startup
BaseLaunch Summer Get-Together 2023
Versameb strengthens its Board of Directors
Cimeio Therapeutics and Prime Medicine announce research collaboration
How Swiss life sciences startups can compete globally
Bridge Biotherapeutics’ partnering strategy and growth by external innovation
Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors
Phialogics closed a €600k pre-seed financing round with HTGF
Do you have a question? Get in touch
info@baselaunch.ch
Contact us
Close Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
News
Events
Contact us